Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-11-14T18:17:53+00:00

The Dimerix Limited Clinical Trials – ACTION for Diabetic Kidney Disease and ACTION for Focal Segmental Glomerulosclerosis – Are Now Open!

Click Here For More Information

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Research

Our lead program DMX-200 is advancing through Phase 2 trials in patients with Chronic Kidney Disease (CKD).

Learn More

Technology

Our Receptor Heteromer Investigation Technology (Receptor-HIT) has been used by global pharmaceutical partners, and supported the development of our own DMX-200 program.

Learn More

Investors

Access the latest company news and information

Visit Investor Centre

Recent news and media

Media Release: DIMERIX DOSES FIRST PATIENT IN DMX-200 CLINICAL TRIAL FOR DIABETIC KIDNEY DISEASE

Read more here.

2018 CEO’s AGM presentation – investor call recording

Dr Nina Webster, CEO of Dimerix, presented to shareholders at the 2018 AGM where she provided a review of key highlights [...]

ASX: AGM Presentation and CEO Address

For the slides presented at the AGM on the 30th October 2018, click here.

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation

Home
Company
Program
Technology
Investors
Contact

© Copyright 2018 Dimerix | Credits

subscribe to patient updates

subscribe to news updates